Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE) on April 26, 2021. Pursuant to the transaction, OSE Immunotherapeutics will receive up to 315 million in potential milestones from Veloxis, including a 7 million upfront payment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.56 EUR | -0.71% | +3.35% | +29.91% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.91% | 128M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OSE Stock
- News OSE Immunotherapeutics
- Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.